ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Gemcitabine

Also written as “gemcitabine”, “gemcitabine hydrochloride” and “AK112, Cadonilimab, nab-paclitaxel, gemcitabine”.

Its studies are mostly in Pancreatic Neoplasms · Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Neoplasms · Biliary Tract Neoplasms, led by 30 companies.

Drug pageGemcitabine: every studyMany companies study it; this page follows only the 128 they lead. All 1,376 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 6, 2000128 company-led studies, 9 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lillyits history only681 open or runningphase 3since Nov 6, 2000Nov 6, 2000May 2027phase 2 · NCT05999994
Hoffmann-La Rocheits history only181 open or runningphase 4since Mar 19, 2008Apr 17, 2007Mar 22, 2027phase 1 · NCT06624085
Pfizerits history only50 open or runningphase 3since Jan 21, 2000Jan 21, 2000none ahead
GlaxoSmithKlineits history only40 open or runningphase 2since May 23, 2003May 23, 2003none ahead
Amgenits history only30 open or runningphase 2since Jul 5, 2000Jul 5, 2000none ahead
Astellas Pharmaits history only20 open or runningphase 1since Apr 9, 2002Apr 9, 2002none ahead
NovoCureits history only20 open or runningphase 2since Oct 23, 2013Oct 23, 2013none ahead
Pierre Fabreits history only20 open or runningphase 2since Apr 16, 2012Apr 16, 2012none ahead
Sarah Cannon Research Instituteits history only20 open or runningphase 2since Apr 4, 2008Apr 4, 2008none ahead
Theriva Biologics SLits history only20 open or runningphase 1since Jan 21, 2014Jan 21, 2014none ahead

Also a collaborator on its studies: Ono Pharmaceutical, Baili-Bio (Chengdu) Pharmaceutical, AbbVie, Bristol-Myers Squibb, Criterium, AstraZeneca, PharmaBio Development, Johnson & Johnson, PPD DEVELOPMENT, LP, Merck, Sanofi and Prologue Research International.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Jun 20, 2007.

  1. Nov 7, 2017Phase 2 study in Carcinoma, Non-Small-Cell LungHoffmann-La Roche · NCT03337698 · 314 enrolled · United States, Australia, France and more
  2. Dec 22, 2017Phase 2 study in Uterine Cervical NeoplasmsHoffmann-La Roche · NCT03386721 · 256 enrolled · United States, Belgium, France and more
  3. Jul 17, 2018Sino Biopharmaceutical’s first study: phase 3 study in Nasopharyngeal CarcinomaNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT03601975 · 336 enrolled · China
  4. Mar 8, 2019Phase 2 study in Carcinoma, Transitional CellHoffmann-La Roche · NCT03869190 · 272 enrolled · United States, France, Greece and more
  5. May 10, 2021EBG MedAustron’s first study: no phase study in Pancreatic NeoplasmsNew to EBG MedAustronEBG MedAustron · NCT04894643 · 10 planned · Austria
  6. Feb 22, 2023Shanghai Miracogen’s first study: phase 3 study in Advanced or Metastatic Urothelium CancerNew to Shanghai MiracogenShanghai Miracogen · NCT05754853 · 290 planned · China
  7. Aug 14, 2023Phase 2 study in NeoplasmsEli Lilly · NCT05999994 · 105 planned · United States, Australia, Belgium and more
  8. Feb 29, 2024Phase 2 study in Pancreatic NeoplasmsNovoCure · NCT06390059 · 84 enrolled · Czechia, Germany, Spain and more
  9. Jun 10, 2024Coherus Oncology’s first study: phase 4 study in Nasopharyngeal NeoplasmsNew to Coherus OncologyCoherus Oncology · NCT06457503 · 100 planned · United States, Canada
  10. Aug 8, 2024Relmada Therapeutics’ first study: phase 2 study in Non-Muscle Invasive Bladder NeoplasmsNew to Relmada TherapeuticsRelmada Therapeutics · NCT06663137 · 70 planned · Israel
  11. Sep 20, 2024Jiangsu Healthy Life Innovation Medical Technology’s first study: no phase study in Biliary Tract NeoplasmsNew to Jiangsu Healthy Life Innovation Medical TechnologyJiangsu Healthy Life Innovation Medical Technology · NCT06611345 · 60 planned · China
  12. Oct 1, 2024Phase 1 study in LymphomaHoffmann-La Roche · NCT06624085 · 50 enrolled · United States, Puerto Rico
  13. Nov 11, 2024BeBetter Med’s first study: phase 2 study in Advanced Triple-Negative Breast CancerNew to BeBetter MedBeBetter Med · NCT06685796 · 65 enrolled · China
  14. Apr 5, 2026Smartwise Sweden AB’s first study: phase 2 study in Pancreatic Cancer Non-resectableNew to Smartwise Sweden ABSmartwise Sweden AB · NCT07575191 · 9 planned · Sweden

Ahead

  1. Dec 2026Primary completion: phase 2 study in Pancreatic NeoplasmsSynerGene Therapeutics · NCT02340117
  2. Dec 31, 2026Primary completion: no phase study in Pancreatic NeoplasmsEBG MedAustron · NCT04894643
  3. Mar 22, 2027Primary completion: phase 1 study in LymphomaHoffmann-La Roche · NCT06624085
  4. May 2027Primary completion: phase 2 study in NeoplasmsEli Lilly · NCT05999994

TargetBeta

“Ribonucleoside-diphosphate reductase RR1 inhibitor”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
HydroxyurearuleNorginephase 415

Studies

The newest 60 of 128 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07575191Pancreatic Cancer Non-resectable · Sweden2RecruitingSmartwise Sweden ABDec 20279
NCT06685796Advanced Triple-Negative Breast Cancer · China2CompletedBeBetter MedApr 20, 202665
NCT06624085Lymphoma · United States, Puerto Rico1Active, not recruitingHoffmann-La RocheMar 22, 202750
NCT06611345Biliary Tract Neoplasms · China–RecruitingJiangsu Healthy Life Innovation Medical TechnologyOct 30, 202660
NCT06663137Non-Muscle Invasive Bladder Neoplasms · Israel2RecruitingRelmada TherapeuticsNov 202770
NCT06457503Nasopharyngeal Neoplasms · United States, Canada4RecruitingCoherus OncologyDec 2027100
NCT06390059Pancreatic Neoplasms · Czechia, Germany, Spain and more2CompletedNovoCureNov 18, 202584
NCT05999994Neoplasms · United States, Australia, Belgium and more2RecruitingEli LillyMay 2027105
NCT05754853Advanced or Metastatic Urothelium Cancer · China3RecruitingShanghai MiracogenOct 2025290
NCT04894643Pancreatic Neoplasms · Austria–RecruitingEBG MedAustronDec 31, 202610
NCT03869190Carcinoma, Transitional Cell · United States, France, Greece and more2TerminatedHoffmann-La RocheOct 8, 2025272
NCT03601975Nasopharyngeal Carcinoma · China3UNKNOWNSino BiopharmaceuticalJul 30, 2020336
NCT03386721Uterine Cervical Neoplasms · United States, Belgium, France and more2TerminatedHoffmann-La RocheDec 30, 2021256
NCT03337698Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more2TerminatedHoffmann-La RocheOct 14, 2025314
NCT03193190Pancreatic Adenocarcinoma · United States, Germany, Japan and more2CompletedHoffmann-La RocheFeb 27, 2025341
NCT02981342Pancreatic Neoplasms · United States, Australia, Belgium and more2CompletedEli LillyApr 20, 2018106
NCT02978716Triple Negative Breast Neoplasms · United States, Belgium, Bulgaria and more2TerminatedPharmacosmosJun 28, 2019102
NCT02941601Thoracic Neoplasms · United States, Belgium, Germany and more2WithdrawnEli LillyDec 20170
NCT03887130Breast Neoplasms2CompletedPierre FabreApr 18, 2013152
NCT02807636Carcinoma, Transitional Cell · United States, Australia, Belgium and more3CompletedHoffmann-La RocheAug 31, 20221,213
NCT02797977Fanconi Anemia · Spain, United Kingdom2CompletedGlaxoSmithKlineApr 8, 2020153
NCT02723331Pancreatic Neoplasms · United States2CompletedAcademic Thoracic Oncology Medical Investigators ConsortiumDec 8, 202248
NCT02565641Pancreatic Neoplasms · Korea, Republic of2CompletedHoffmann-La RocheSep 200663
NCT02340117Pancreatic Neoplasms · United States2Active, not recruitingSynerGene TherapeuticsDec 202628
NCT02237157Pancreatic Neoplasms · United States1CompletedRenovoRxSep 201620
NCT02194556Adenocarcinoma · China4UNKNOWNBetta PharmaceuticalsJul 2017100
NCT02045602Neoplasms · Spain1CompletedTheriva Biologics SLMay 201942
NCT02045589Neoplasms · Spain1CompletedTheriva Biologics SLOct 20168
NCT02006667Urologic Neoplasms · Germany2CompletedHoffmann-La RocheJan 201013
NCT01971281Pancreatic Neoplasms · Spain, Switzerland2UNKNOWNNovoCureDec 201740
NCT01684878Ovarian Neoplasms · Austria, Belgium, Denmark and more3CompletedHoffmann-La RocheJan 30, 2015208
NCT01606748Carcinoma, Non-Small-Cell Lung · United States2CompletedEli LillyJun 201335
NCT01599013Carcinoma, Transitional Cell · France2CompletedPierre FabreOct 201369
NCT01564251Lymphoma · United States, France1CompletedHoffmann-La RocheJan 11, 2018104
NCT01359696Solid Tumor · United States, France1CompletedHoffmann-La RocheMay 29, 201440
NCT01324258Pancreatic Neoplasms · Japan1CompletedGlaxoSmithKlineJul 8, 201319
NCT01201265Breast Neoplasms · India2CompletedHoffmann-La RocheApr 201540
NCT01185847Non-Squamous Non-Small Cell Lung Cancer · Belgium, France, Germany and more2CompletedHoffmann-La RocheSep 201290
NCT01160744Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more2CompletedEli LillyJan 2014280
NCT01126749Urinary Bladder Neoplasms · United States, Germany, Netherlands and more2TerminatedEisaiMay 8, 201592
NCT01077713Non-Squamous Non-Small Cell Lung Cancer · Italy2CompletedHoffmann-La RocheJul 201486
NCT01010945Adenocarcinoma · United States1CompletedAstellas PharmaJan 25, 201219
NCT00846027Breast Neoplasms · Spain2CompletedHoffmann-La RocheDec 201190
NCT00821327Urothelial Cancer · United States2CompletedSarah Cannon Research InstituteAug 201236
NCT00701558Non-small Cell Lung Cancer Metastatic · Romania2CompletedHoffmann-La RocheOct 201020
NCT00678977Carcinoma, Non-Small-Cell Lung · Germany, United Kingdom1CompletedGlaxoSmithKlineMar 30, 201022
NCT00656084Recurrence2CompletedSarah Cannon Research InstituteJan 200716
NCT00642733Pancreatic Neoplasms · Mexico4TerminatedHoffmann-La RocheApr 20096
NCT00623233Breast Neoplasms · United States2CompletedEli LillyJan 201152
NCT00615446Neoplasms · United States1CompletedPfizerMay 200944
NCT00613730Pancreatic Neoplasms2TerminatedAmgenApr 20093
NCT00536770Pancreatic Neoplasms · United States2SuspendedNovacea132
NCT00491127Lymphoma, Non-Hodgkin · Spain2CompletedEli Lilly10
NCT00491114Urinary Bladder Neoplasms · Italy2CompletedEli Lilly8
NCT00490880Urinary Bladder Neoplasms · Poland2CompletedEli Lilly2
NCT00490711Carcinoma, Ovarian Epithelial · Slovakia2CompletedEli Lilly7
NCT00490659Carcinoma, Non-Small-Cell Lung · Poland2CompletedEli Lilly13
NCT00490399Biliary Tract Carcinoma · Korea, Republic of2CompletedEli Lilly39
NCT00489996Carcinoma, Non-Small-Cell Lung · China2CompletedEli Lilly100
NCT00489983Carcinoma, Non-Small-Cell Lung · Germany, Italy, United Kingdom2CompletedEli Lilly91

How it is read

Names in the registry

  • “Gemcitabine”, 113 entries
  • “gemcitabine”, 52 entries
  • “gemcitabine hydrochloride”, 17 entries
  • “AK112, Cadonilimab, nab-paclitaxel, gemcitabine”, 3 entries
  • “EndoTAG-1 and Gemcitabine”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.